Previous close | 2.5600 |
Open | 2.7000 |
Bid | 0.0000 |
Ask | 4.6000 |
Strike | 570.00 |
Expiry date | 2024-06-21 |
Day's range | 2.5600 - 2.7000 |
Contract range | N/A |
Volume | |
Open interest | 17 |
Key Insights Institutions' substantial holdings in Regeneron Pharmaceuticals implies that they have significant...
Q1 2024 Intellia Therapeutics Inc Earnings Call
Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing Phase 1/2 CHORD trial is currently enrolling infants and children in the U.S., UK and Spain TARRYTOWN, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) wi